FONAR CORP

Company Overview

FONAR Corporation designs, manufactures and services the Upright® MRI scanner and operates a captive diagnostic-services business through Health Management Corporation of America (HMCA), which manages 44 MRI scanners and owns six Florida diagnostic facilities. The business combines one-time equipment sales with recurring service, upgrade and captive-scan volume revenue; HMCA drove the majority of FY2025 revenue ($95.4M) while service and aftermarket revenue (~$8.4M) and management fees provide recurring cash. The company highlights a large patent portfolio (245 issued patents) and modest R&D (~$1.58M in FY2025) focused on software and positioning innovations, while facing concentrated payer exposure (no-fault/workers’ comp) and regulatory risk across FDA, Stark/Anti‑Kickback, HIPAA and state tort regimes. Management reported modest top-line growth but compressed operating margins in FY2025, with elevated credit-loss reserves and one-time items hurting profitability; a CEO/COO-led nonbinding take-private proposal is currently under Special Committee review.

Executive Compensation Practices

Given FONAR’s mixed model (equipment sales plus recurring diagnostic services), executive pay is likely tied to a combination of financial and operational metrics that drive both near-term cash and long‑term installed‑base value — e.g., HMCA revenue/scan volumes, service and upgrade revenue, operating income or adjusted EBITDA, and working capital/receivables collectability. Industry norms in Healthcare / Diagnostics & Research favor modest base salaries with annual cash incentives and long‑term equity (stock options or restricted stock) to align executives with multi-year device adoption, service recurring revenue and patent-driven differentiation; modest R&D spend suggests stronger emphasis on commercial and service KPIs than milestone-based R&D awards. Given regulatory exposure (FDA, Stark, Anti‑Kickback, HIPAA) and the company’s reliance on payer dynamics, compensation plans may include compliance and quality metrics and could feature clawback provisions or bonus adjustments tied to legal/regulatory outcomes and reimbursements. The recent profitability decline, CECL provisioning and a potential go‑private transaction increase the likelihood that compensation committees will emphasize cash generation, balance-sheet stability, and transaction-related governance in short‑term bonuses and equity vesting decisions.

Insider Trading Considerations

FONAR’s concentrated insider ownership and the disclosed CEO/COO-led take‑private proposal raise heightened surveillance needs for related-party transactions, director recusal disclosures and Form 4 filings; any insider purchases or sales tied to the transaction will attract scrutiny and could materially move the stock. As a Section 16 reporting company, officers and directors are subject to short‑swing profit rules and must promptly disclose trades; look for use of 10b5‑1 trading plans as a signal of pre‑planned, compliant activity versus opportunistic trades. Key business drivers that historically move the stock — reimbursement updates (especially no‑fault/workers’ comp and Florida tort law), large reserves (ATIC/CECL), new site installs or high‑field magnet additions, and FDA/clinical developments — create periodic windows where insiders may be informed and therefore subject to blackout periods and stricter trading protocols. Finally, healthcare regulatory risks and potential clawbacks tied to compliance failures mean researchers and traders should monitor insider option exercises, equity grant timing, and any special committee disclosures for conflicts or non‑routine compensation actions.